Moderna, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 17.74B | 18.88B | 6.85B | 3.20B | 1.94B | -39.2% | |
| Cost of Revenue | (2.62B) | (5.42B) | (4.69B) | (1.46B) | (868.00M) | -40.7% | |
Gross Profit | 15.12B | 13.46B | 2.15B | 1.74B | 1.08B | -38.0% | |
| Operating Expenses | |||||||
| Research & Development | (1.99B) | (3.29B) | (4.84B) | (4.54B) | (3.13B) | -31.1% | |
| Selling, General & Administrative | (567.00M) | (1.13B) | (1.55B) | (1.17B) | (1.02B) | -13.3% | |
| Depreciation & Amortization | (232.00M) | (348.00M) | (621.00M) | (189.00M) | (215.00M) | 13.8% | |
Operating Income (EBIT) | 13.30B | 9.42B | -4.24B | -3.94B | -3.07B | -22.1% | |
| Non-Operating Items | |||||||
| Interest Income | 18.00M | 200.00M | 421.00M | 425.00M | 314.00M | -26.1% | |
| Interest Expense | (18.00M) | (29.00M) | (38.00M) | (24.00M) | (10.00M) | -58.3% | |
| Other Income/Expenses (Net) | -11.00M | 155.00M | 297.00M | 338.00M | 306.00M | -9.5% | |
Income Before Tax | 13.29B | 9.57B | -3.94B | -3.61B | -2.77B | -23.3% | |
| Income Tax Expense | (1.08B) | (1.21B) | (772.00M) | (46.00M) | (54.00M) | -217.4% | |
Net Income | 12.20B | 8.36B | -4.71B | -3.56B | -2.82B | -20.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $30 | $21 | $-12 | $-9 | $-7 | -21.7% | |
| Weighted Avg Shares Outstanding | 403.00M | 394.00M | 382.00M | 384.00M | 389.00M | 1.3% | |
| Weighted Avg Shares Outstanding (Diluted) | 431.00M | 416.00M | 382.00M | 384.00M | 389.00M | 1.3% | |
EBITDA | 13.54B | 9.95B | -3.28B | -3.39B | -2.55B | -24.8% |
Explore MRNA
MRNA in the Healthcare
Large Cap